Back to Results

UCB SA ADR (UCBJY)

UCB SA ADR is a depositary receipt representing common stock of UCB SA, a biopharmaceutical company headquartered in Brussels, Belgium. The underlying issuer focuses on treatments and solutions for neurology and immunology conditions worldwide. Its commercial portfolio includes therapies such as Cimzia for several inflammatory diseases, Vimpat, Keppra and Briviact for epilepsy, Neupro for Parkinson’s disease and restless legs syndrome, and Nayzilam for epilepsy seizure clusters. UCB also markets allergy products Zyrtec and Xyzal, osteoporosis treatment Evenity, and Bimzelx for plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa and axial spondyloarthritis. The company further develops a pipeline that includes candidates for rare diseases, autoimmune conditions, neurodegenerative disease and respiratory disorders, and it also conducts contract manufacturing activities.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-UCBJ.Y
$152.05
10.2% Upside
Fair
$162.64
17.9% Upside
Fair
Great
—
—
0.53
0.4%
July 30, 2026
29.0x
4.2x
5.8x
51.749 B
53.02 B
4.7%
63.0%
10.3
16.9%
129.0%
Send a message
Valuation • Fair Value

UCB SA ADR (OTC-UCBJ.Y) Fair Value by Valuation Model

Compare the primary fair value estimate for UCB SA ADR (OTC-UCBJ.Y) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$152.05

Estimated upside of 10.2% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$173.30

Discounted cash flow valuation reference.

Ben Graham Formula Value

$53.28

Classic Ben Graham valuation formula reference.

DDM Fair Value

$137.81

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$133.17

Comparable-company valuation reference.

Analyst Price Target

$162.64

Analysts imply upside of 17.9%.

How to read these valuation models

Use this section to compare the primary fair value estimate for UCB SA ADR (OTC-UCBJ.Y) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for UCB SA ADR (OTC-UCBJ.Y)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

9.094 B

Current operating scale indicator.

Revenue Forecast

9.701 B

Forward revenue estimate.

EBITDA

3.071 B

Current operating profitability reference.

EBITDA Forecast

3.322 B

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review UCB SA ADR (OTC-UCBJ.Y) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for UCB SA ADR (OTC-UCBJ.Y)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

8

Relatively strong quality score.

Beneish M-Score

-2.41

No elevated caution signal from this screen.

Altman Z-Score

10.3

Relatively strong balance-sheet zone.

FCF / Net Income

129.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for UCB SA ADR (OTC-UCBJ.Y). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for UCB SA ADR (OTC-UCBJ.Y)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 30, 2026

Days to Earnings

9

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.4%

Income yield reference.

Upcoming Dividend

0.53

Upcoming distribution amount.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

16.9%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for UCB SA ADR (OTC-UCBJ.Y), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

UCB SA ADR (OTC-UCBJ.Y) Stock Forecast & Technical Outlook

Review UCB SA ADR (OTC-UCBJ.Y) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for UCB SA ADR (OTC-UCBJ.Y) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for UCB SA ADR (OTC-UCBJ.Y) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for UCB SA ADR (OTC-UCBJ.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for UCB SA ADR (OTC-UCBJ.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for UCB SA ADR (OTC-UCBJ.Y) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for UCB SA ADR (OTC-UCBJ.Y)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, UCB SA ADR (OTC-UCBJ.Y) has a Strong Buy consensus, with 2 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 0
Sell 0
FAQ • Fast Investor Answers

UCB SA ADR (OTC-UCBJ.Y) Stock FAQ

Quick answers about UCB SA ADR (OTC-UCBJ.Y) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$152.05
Estimated upside 10.2%
Valuation Rating
Undervalued
Estimated upside of 10.2%
Analyst Target
$162.64
Implied upside 17.9%
Financial Health
Great
Current financial-health read

The current fair value estimate for UCB SA ADR (OTC-UCBJ.Y) is $152.05. This implies an estimated upside of 10.2% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 10.2% versus the current market price.

The available analyst price target for UCB SA ADR (OTC-UCBJ.Y) is $162.64. The analyst target implies estimated upside of 17.9%.

The current financial health read for UCB SA ADR (OTC-UCBJ.Y) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for UCB SA ADR (OTC-UCBJ.Y) is July 30, 2026.

Based on the current data, dividend yield is 0.4%, upcoming dividend amount is 0.53.

The current P/E ratio listed for UCB SA ADR (OTC-UCBJ.Y) is 29.0x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for UCB SA ADR is 51.749 B.

The current enterprise value listed for UCB SA ADR is 53.02 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for UCB SA ADR is OTC-UCBJ.Y, and the stock is listed on OTC Markets.

UCB SA ADR (OTC-UCBJ.Y) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for UCB SA ADR is 4.7%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for UCB SA ADR is 63.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on OTC Markets View more

Roche Holding AG Participation (RHHVF) Roche Holding AG Participation (RHHVF)
Roche Holding Ltd ADR (RHHBY) Roche Holding Ltd ADR (RHHBY)
Novartis AG (NVSEF) Novartis AG (NVSEF)
GSK plc (GLAXF) GSK plc (GLAXF)
Chugai Pharmaceutical Co Ltd ADR (CHGCY) Chugai Pharmaceutical Co Ltd ADR (CHGCY)
Merck KGaA ADR (MKKGY) Merck KGaA ADR (MKKGY)
Takeda Pharmaceutical Co., Ltd. (TKPHF) Takeda Pharmaceutical Co., Ltd. (TKPHF)
Bayer AG PK (BAYRY) Bayer AG PK (BAYRY)
Otsuka Holdings Co Ltd ADR (OTSKY) Otsuka Holdings Co Ltd ADR (OTSKY)
Sandoz Group AG (SDZXF) Sandoz Group AG (SDZXF)
Daiichi Sankyo Co Ltd ADR (DSNKY) Daiichi Sankyo Co Ltd ADR (DSNKY)
Astellas Pharma Inc (ALPMY) Astellas Pharma Inc (ALPMY)
Ipsen SA ADR (IPSEY) Ipsen SA ADR (IPSEY)
Shionogi & Co Ltd ADR (SGIOY) Shionogi & Co Ltd ADR (SGIOY)
CSPC Pharmaceutical Group Ltd (CHJTF) CSPC Pharmaceutical Group Ltd (CHJTF)
Orion Oyj ADR (ORINY) Orion Oyj ADR (ORINY)
Sino Biopharmaceutical Ltd ADR (SBHMY) Sino Biopharmaceutical Ltd ADR (SBHMY)
Eisai Co (ESALF) Eisai Co (ESALF)
Ono Pharmaceutical Co Ltd (OPHLY) Ono Pharmaceutical Co Ltd (OPHLY)
Hikma Pharmaceuticals PLC ADR (HKMPY) Hikma Pharmaceuticals PLC ADR (HKMPY)
Aspen Pharmacare Holdings Ltd ADR (APNHY) Aspen Pharmacare Holdings Ltd ADR (APNHY)
Santen Pharmaceutical Co (SNPHY) Santen Pharmaceutical Co (SNPHY)
Hypera SA ADR (HYPMY) Hypera SA ADR (HYPMY)
Haw Par Corporation Ltd ADR (HAWPY) Haw Par Corporation Ltd ADR (HAWPY)